Biotechs seek treasure in pharma castoff, antibiotics

Antibiotics lack the revenue luster to keep pharma engaged, and only three have been approved by the FDA since 2006. But the niche looks good to some biotechs. "A smaller, more manageable product with revenue under $1 billion is fine for a biotech company," Needham & Co. analyst Alan Carr tells Bloomberg. Story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)